I'm referring to the announcement last August.
4 patients treated in a trial that ran for 2.5 years. Management kept being extremely coy about details of trial progress.
I suppose it was really 2 years, with the clinical trial website stating that the trial had ceased due to poor patient enrollment in Dec 2022. It just took management another 8 months to update shareholders.
That's definitely what I'd call a trial failure. Management, governance and communication failures also.
Ann: Positive Ph I/II DFI Efficacy Data to Support Site Expansion, page-24
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
-0.005(1.61%) |
Mkt cap ! $87.95M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 32.0¢ | 29.5¢ | $30.39K | 99.67K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 25190 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 3178 | 6 |
View Market Depth
| Last trade - 14.05pm 26/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |